Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of masitinib plus riluzole versus placebo plus riluzole in amyotrophic lateral sclerosis
MOH_2017-07-09_000594Phase 3Not yet recruiting
- Sponsor
- AB Science
- Start
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Masitinib + riluzole with Placebo + riluzole (2 arms). Planned start Feb 2017; status: not yet recruiting.
02
Drugs
masitinib
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on MOH_2017-07-09_000594.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-07-09_000594.